Results 101 to 110 of about 2,492,664 (191)

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

Histopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung, Esther Baranov, Isairis Peralta Valerio, Robin Collingwood, Natalie Respond, Don Siegel, Pooja Devi, Kristen M. Stashek   +7 more
wiley   +1 more source

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients

Therapeutics and Clinical Risk Management, 2017
Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro ...
AlDallal SM
doaj  

ICSH Guidance on Bone Marrow Examination and Reporting

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease
Wendy N. Erber, Alexandar Tzankov, Olga Pozdnyakova, Hiromichi Matsushita, Gina Zini, Leonie Saft, on behalf of the International Council for Standardization in Haematology   +6 more
wiley   +1 more source

Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy

Canadian Journal of Gastroenterology, 2013
BACKGROUND: Although most patients with autoimmune hepatitis (AIH) respond to treatment with prednisone and/or azathioprine, some patients are intolerant or refractory to standard therapy.
Kelly W Burak, Mark G Swain, Tania Santodomino-Garzon, Samuel S Lee, Stefan J Urbanski, Alexander I Aspinall, Carla S Coffin, Robert P Myers   +7 more
doaj   +1 more source

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

OncoImmunology, 2018
Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 ...
Shlomo Elias, Shira Kahlon, Rebecca Kotzur, Noah Kaynan, Ofer Mandelboim   +4 more
doaj   +1 more source

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Assessment of Clinical and Immunological Factors of Local Recurrence in Canine Soft Tissue Sarcoma

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Canine soft tissue sarcomas (STSs) are locally invasive tumours, making local recurrence a major clinical challenge. Time to recurrence (TTR) and associated immune factors remain poorly characterized. This study aimed to characterize the immune microenvironment of canine STS and identify factors associated with TTR.
Kazuki Mizuta, Helene Philibert, Arata Matsuyama   +2 more
wiley   +1 more source

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study

, 2010
To investigate the safety and efficacy of ofatumumab, a novel human anti-CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to > or = 1 disease-modifying antirheumatic ...
Wiell, Charlotte, Østergaard, Mikkel, Sierakowski, Stanislaw, Rigby, William, Rojkovich, Bernadette, Dawes, Peter T, Tamer, Søren C, Wallace, Daniel J, Kastberg, Helle, Baslund, Bo, Jorgensen, Christian, Petersen, Jørgen, Stanislaw Sierakowski, Bo Baslund, Christian Jorgensen, Daniel J. Wallace, Charlotte Wiell, Helle Kastberg, Mikkel Østergaard, Peter T. Dawes, Søren C. Tamer, William Rigby, Bernadette Rojkovich, Jørgen Petersen   +23 more
core   +1 more source

Cox‐PASNet With Late Fusion of Transcriptomic and Clinical Features for Survival Prediction in Diffuse Large B‐Cell Lymphoma

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Accurate prognosis in diffuse large B‐cell lymphoma (DLBCL) remains a clinical challenge. The International Prognostic Index (IPI) is the standard tool but relies solely on clinical variables and fails to capture the extensive molecular heterogeneity of DLBCL.
Auguste Rumbutyte, Jonathan Pearson, Scarlett Kynoch   +2 more
wiley   +1 more source